Bayer S(+)ibuprofen fever study data needed; FDA committee votes against approval.
This article was originally published in The Tan Sheet
BAYER S(+)IBUPROFEN FEVER REDUCTION STUDY NEEDED, FDA's Nonprescription Drugs and Arthritis Drugs Advisory Committees concluded at an Oct. 9 joint meeting in Bethesda, Md. The committees voted 9-1 not to recommend Bayer's S(+)ibuprofen (dexibuprofen) 200 mg caplets for approval as an OTC analgesic (NDA 20-373). Bayer's proposed indications are the temporary relief of minor aches and pains associated with the common cold, headache, toothache, muscle aches, back ache, menstrual cramps, minor pain of arthritis and temporary reduction of fever ("The Tan Sheet" Sept. 9, p. 3).
You may also be interested in...
Rx-to-OTC switches of the painkillers dexibuprofen and single-pill combinations of ibuprofen and paracetamol as well as the cough medicine levodropropizine, all for oral use, will be considered at the next German Expert Committee for Prescription meeting on 13 July.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning